Comparative Discriminative Performance of the HbA1c/HDL-C Ratio, Stress Hyperglycemia Ratio, and ZJU Index for HOMA-IR-Defined Insulin Resistance in Patients With Type 2 Diabetes.
Аннотация
BACKGROUND
Routine assessment of insulin resistance (IR) remains challenging because fasting insulin measurements are not routinely available in many clinical settings. Several readily available metabolic indices, including the HbA1c/HDL-C ratio, stress hyperglycemia ratio (SHR), and Zhejiang University (ZJU) index, have been associated with IR or related metabolic disturbances. However, their relative discriminative performance for HOMA-IR-defined IR in patients with established Type 2 diabetes has not been systematically compared. We aimed to compare their discriminative performance for HOMA-IR-defined IR and to assess whether ZJU provides incremental discrimination beyond conventional clinical and metabolic characteristics.
METHODS
This was a single-center retrospective cross-sectional study. We included 1000 hospitalized adults with established T2DM. HOMA-IR was calculated from fasting plasma glucose and fasting insulin, and IR was operationally defined as HOMA-IR ≥ 2.69. Multivariable logistic regression and restricted cubic spline analyses evaluated associations and nonlinear associations. Receiver operating characteristic analyses with paired DeLong tests compared discriminative performance. Additional analyses included TyG and TyG-BMI, comparisons with individual ZJU components, nested-model analysis, decision-curve analysis, bootstrap internal validation, and medication-adjusted sensitivity analyses.
RESULTS
All three indices were significantly associated with HOMA-IR-defined IR after multivariable adjustment. Compared with the lowest quartile, the adjusted odds ratios in the highest quartile were 3.16 (95% CI 1.95-5.18) for the HbA1c/HDL-C ratio, 6.86 (4.11-11.84) for SHR, and 18.36 (10.21-34.79) for ZJU. Significant nonlinear associations were observed for all three indices. Among the evaluated composite indices, ZJU had the highest AUC (0.777, 95% CI 0.742-0.812), followed by TyG (0.749, 0.712-0.785), TyG-BMI (0.733, 0.695-0.770), SHR (0.698, 0.659-0.738), and HbA1c/HDL-C (0.615, 0.573-0.657). ZJU did not significantly outperform FPG alone (AUC 0.766; p = 0.509). Adding ZJU to the basic clinical model increased the AUC from 0.658 to 0.780 (ΔAUC = 0.123; p < 0.001), whereas adding ZJU to a more comprehensive model including its major metabolic components did not improve discrimination (0.806 vs. 0.807; p = 0.983).
CONCLUSIONS
In hospitalized patients with established T2DM, ZJU demonstrated moderate discrimination for HOMA-IR-defined IR and provided incremental discrimination beyond basic clinical characteristics.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.